In recent research on cancer therapy, oncolytic viruses start to show their great promise in cancer killing. As an experienced supplier in biotech markets, Creative Biolabs is skilled at providing oncolytic virus development services to suit every client’s specific needs.
In May 2019, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to MB-108 (oncolytic virus C134) for the treatment of malignant glioma. And then, On 24th. October, 2019, the safety and efficacy of MB-108 were proved in Phase 1 clinical trial, which shows another contribution that oncolytic viruses (OVs) have made for treatment of cancer.
Twenty years of oncolytic virus development have created a field that is driven by the potential promise of lasting impact on cancer treatment repertoire. With the field constantly expanding – over 20 viruses have been recognized as potential OVs – new virus candidates continue to emerge even as established viruses reach clinical trials.
With years of exploration in OVs, Creative Biolabs has accumulated an increasing experience in oncology, and has built up a systemic R&D mode in oncotherapy. The OncoVirapy™ platform has been developed by integrating the technologies of viral biology, immunology and genetic engineering, taking advantage of which, Creative Biolabs is confident to provide a wide range of OV engineering scoop including but not limited to Adenovirus, Adeno-Associated Virus, Measles Virus, Vesicular Stomatitis Virus and Herpes Simplex Virus.
The OVs can be manipulated to alter the capsid to reduce pathogenicity and immunogenicity, to secret antibody to boost the anti-tumor immune response, to be loaded with immune checkpoint inhibitors, etc. Scientists in Creative Biolabs have developed strategies to deliver customized engineered OVs for different research use. To ensure a comprehensive R&D process, in vitro and in vivo validation studies for each developed OV based upon the properties of targeting disease, characteristics of virus, mechanism of actions are necessary. Based on the validation result, the established oncolytic virotherapy can be further optimized for safer and enhanced anticancer effect.
With all these steps, pre-made oncolytic virus with high quality and customized characteristics is also available to accelerate the research progress for clients worldwide. The state-of-the-art OV engineering platform is able to provide a series of purified pre-made OV for reporter-encoding, cytokine-expressing, immune checkpoint antibody-arming, capsid-modifying and miRNA-expression.
Besides, Creative Biolabs take OV as the lead in disease-specific oncolytic virotherapy development. Following systematic consideration, the well-designed recombinant virus will be constructed and then undergo a series of in vitro assays to test the replication capacity, tumor cell killing ability, and also the expression and function of the transgene. Furthermore, a comprehensive and rational design of in vivo study will be performed to fully validate the therapeutic effect of OV in related disease models. In addition, proof-of-concept study for combination therapeutic strategy is also available on the platform.
The therapeutic strategies involving OVs rise again as a promising field to discover in cancer immunotherapy. Creative Biolabs will keep optimizing and expanding our services in cancer immunotherapy to meet the demand of next generation of cancer therapy. Further information can be found on: https://www.creative-biolabs.com/oncolytic-virus.
About Creative Biolabs
With years of study and experience in cancer immunotherapy development and virotherapy, Creative Biolabs, a leading company providing customized, standardized, reliable and high-quality oncolytic virus therapy development services, covers oncolytic virus design and construction, oncolytic virus engineering, in vitro and in vivo validation, and other featured oncolytic virotherapy development services for various type of tumors and for combination with other therapies.